Responsible Corporate Officers in the Pharmaceutical Industry: Who Directed the Fraud, and Who Can Expose It?

The pharmaceutical responsible corporate officer doctrine can reach officers with authority to prevent or correct drug misbranding, even without personal participation. An employee who carried out instructions can still be a pharmaceutical whistleblower. Who designed the scheme, who followed directions and who could have stopped it are different questions. If your part was delivering the sales message someone else chose, that distinction matters.

Can an Employee Who Followed Instructions Still Be a Whistleblower?

Yes. An employee who carried out a pharmaceutical fraud under instruction can still bring a whistleblower case. The False Claims Act distinguishes participation from planning and initiating the violation. Your part in the work belongs in the conversation with our whistleblower experts, alongside what you know about the people directing it.

The False Claims Act’s whistleblower provisions let a court reduce the share of someone who planned and initiated the violation. A person convicted of criminal conduct arising from their role in that violation is dismissed from the civil case and receives no share. Planning alone does not automatically end a whistleblower’s share. The court decides whether to reduce it.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We work through your role with you.

Purdue Frederick Put the Sales Instructions in View

Purdue Frederick shows why the difference between giving instructions and carrying them out matters. The company admitted falsely promoting OxyContin as less addictive, less subject to abuse and less likely to cause withdrawal than other pain medications. Its May 2007 case announcement describes a message built into training and delivered by the sales force.

Supervisors and employees sponsored training using graphs that exaggerated differences between OxyContin and immediate-release opioids. New representatives practiced with similar graphs in role-play training at headquarters. Supervisors also instructed representatives to use language from the package insert to promote reduced abuse potential.

For a pharmaceutical sales representative, those training materials connect the claim made in the doctor’s office to what supervisors taught at headquarters. Knowing who supplied the message and what the training required can help distinguish the employee’s role from the decisions behind it.

The case also exposed a contradiction inside the company. Sales representatives distributed an article to support claims that patients taking lower doses could stop abruptly without withdrawal symptoms. Purdue had received information about possible withdrawal symptoms in study patients. After a further review identified more such reports, supervisors and employees decided against writing up the findings because of concern about negative press.

Doctors and patients were being sold reassurance about risks the company’s own information called into question. An insider’s account of instructions, scientific findings and the response to those findings can matter as much as the final sales material.

What Does the Responsible Corporate Officer Doctrine Require?

The responsible corporate officer doctrine requires responsibility and authority to prevent or correct the company’s violation of the Food, Drug, and Cosmetic Act. The question is who had the power to stop the misleading promotion.

The Supreme Court’s 1943 decision put responsibility on people whose positions connected them to a danger to public health. Its 1975 decision said they must look for violations, fix them and take steps to prevent them.

For an insider, the useful question is what the person could actually change. Who controlled the sales instructions? Who could correct a misleading claim? Who had authority over the work when the problem continued?

A civil False Claims Act case also follows the government money. The law reaches someone who knowingly submits or causes a false claim for payment. In pharmaceutical cases, the manufacturer can cause claims that a pharmacy or physician submits. We connect the directions inside the business to the prescriptions and government payments they produced.

The Officers’ Responsibility Was Different From the Company’s Fraud

Purdue Frederick pleaded guilty to felony misbranding with intent to defraud or mislead. Its president and chief operating officer, executive vice president and chief legal officer, and former executive vice president of worldwide medical affairs pleaded guilty to misdemeanor misbranding. The officers admitted responsibility and authority to prevent or promptly correct the misrepresentations.

The appeals court stated the distinction directly:

The company admitted fraudulent marketing. The officers admitted failing to prevent it.

The court described approximately $600 million in company monetary sanctions for a fraud the officers admitted they had authority to prevent or correct. The officers had to return approximately $34.5 million in compensation between them. The Justice Department separately identified $160 million of the company’s payments as resolving false claims involving Medicaid and other government healthcare programs.

Purdue Frederick Officers’ Exclusion Duration and Remand

The Purdue Frederick officers’ exclusion duration went back to the agency for a reasoned explanation in July 2012.

Exclusion concerns participation in federal health care programs. It prevents reimbursement under Medicare, Medicaid and other federal programs for items and services furnished, ordered or prescribed by an excluded person.

The agency initially set the officers’ exclusions at 20 years. It reduced them to 15 years for their assistance to law enforcement, and an appeals board cut them to 12 years. The court accepted the power to exclude the officers because their misdemeanor convictions related to the company’s fraudulent misbranding.

The court said the agency had compared the officers to very different cases and had to explain the length it chose. It sent the duration back for reconsideration.

What Evidence Is Needed to Prove Fraud?

For a pharmaceutical whistleblower case, the evidence connects the company’s conduct and knowledge to false government claims. For the roles inside that conduct, it also matters who chose the practice, who was instructed to carry it out and who had authority to correct it. We examine those connections with you.

The person presenting a graph to a doctor may see something different from the person who reviewed the study behind it. Purdue’s training and withdrawal-data history shows why both perspectives matter.

A clinical or regulatory affairs employee may recognize the gap between the study findings and the message given to the sales force. A representative may know how that message was taught. Someone in management may know where corrective authority sat. We put those accounts together to understand the decisions behind the conduct and the government payments at issue.

Public Citizen’s 2018 report, Twenty-Seven Years of Pharmaceutical Industry Criminal and Civil Penalties: 1991 Through 2017, found that whistleblower disclosures contributed at least in part to 71% of federal penalties in its study. The same report described financial sanctions against executives as rare.

When You Know Where the Instructions Came From

If you delivered the sales message, reviewed the contradictory data or saw who kept a practice going, speak to one of our whistleblower experts about where the instructions came from. We work beside you to build your strongest pharmaceutical whistleblower case and bring in pharmaceutical fraud whistleblower lawyers who understand the difference between designing a scheme and carrying out instructions.